Valbiotis Announces Its Combined Shareholders General Meeting Will Be Held on May 2, 2023
2023年4月15日 - 12:40AM
ビジネスワイヤ（英語）
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible)
(Paris:ALVAL), a commercially oriented Research and Development
company, committed to scientific innovation for preventing and
combating metabolic and cardiovascular diseases, announces its
Combined Shareholders Meeting will be held on May 2, 2023, and
releases the procedures for making available and consulting
preparatory documents.
The Shareholders’ Meeting will be held at:
L’Espace ENCAN – Quai Louis Prunier –17000 La
Rochelle May 2, 2023, at 9.30 am
The Shareholders who wish to attend the Shareholders’ Meeting
must hold an admission card and an identity document.
The Valbiotis Board of Directors invites shareholders to vote on
resolutions, particularly Resolutions n°4 & 5 relating to the
renewal of the independent members of the Supervisory Board, Mr
ZETLAOUI and Mr LEVY, and draws their attention to the publication
of a complementary report, dated April 6, 2023, that supplements
the content of the Board of Directors’ management report and the
Supervisory Board's report on corporate governance as of March 14,
2023, highlighting namely the independent nature of the members of
the Supervisory Board, as defined in the corporate governance code
as amended in September 2021 by MiddleNext.
The means of taking part in the Shareholders’ Meeting and the
draft proposed resolutions were published in the Bulletin des
Annonces Légales Obligatoires (BALO) on March 24, 2023, in Issue
No. 36 (https://www.journal-officiel.gouv.fr/pages/balo/).
The convening notice, including the agenda and the final
resolutions projects, as well as the modalities of participation
and vote at the General Meeting, was published on the Company
website and in the Bulletin des Annonces Légales Obligatoires
(BALO) on April 12, 2023, in Issue No. 44
(https://www.journal-officiel.gouv.fr/pages/balo/).
All the documents related to the May 2, 2023 Combined General
Meeting, in accordance with Article R.22-10-23 of the French
Commercial Code, can be accessed on the Valbiotis website at the
following section: www.valbiotis.com/en/general-assemblies/.They
will also be available at the Company headquarters or by mail at:
contact@valbiotis.com.
The documents and information concerning the Shareholders’
Meeting will be made available to shareholders as provided by
applicable regulations.
About Valbiotis
Valbiotis is a commercially oriented Research & Development
company, committed to scientific innovation for preventing and
combating metabolic and cardiovascular diseases in response to
unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to
revolutionize healthcare by developing a new class of health
nutrition products designed to reduce the risk of major metabolic
diseases, relying on a multi-target strategy enabled by the use of
plant-based terrestrial and marine resources.
Internationally, its products are intended to be the subject of
licensing and/or distribution agreements with global or regional
health and nutrition players. In France, Valbiotis will be
responsible for marketing its own products.
Created at the beginning of 2014 in La Rochelle, the Company has
forged numerous partnerships with leading academic centers. The
Company has established three sites in France – Périgny, La
Rochelle (17) and Riom (63) – and a subsidiary in Quebec City
(Canada).
Valbiotis is a member of the "BPI Excellence" network and has
been recognized as an "Innovative Company" by the BPI label.
Valbiotis has received major financial support from the European
Union for its research programs via the European Regional
Development Fund (ERDF). Valbiotis is a PEA-SME eligible
company.
For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
filed to the French Financial Markets Regulator (AMF) on May 19,
2022 and completed by an amendment on November 8, 2022. This
document is available on the Company’s website
(www.valbiotis.com).
This press release and the information it contains do not
constitute an offer to sell or subscribe, or a solicitation to
purchase or subscribe to Valbiotis’ shares or financial securities
in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230414005168/en/
Corporate communication / Valbiotis Carole ROCHER Communication
and Public Affairs Director + 33 6 77 82 56 88
Marc DELAUNAY Communication Manager media@valbiotis.com
Financial communication / Seitosei Actifin Stéphane RUIZ
Associate Director +33 1 56 88 11 14 sruiz@actifin.fr
Valbiotis (EU:ALVAL)
過去 株価チャート
から 11 2024 まで 12 2024
Valbiotis (EU:ALVAL)
過去 株価チャート
から 12 2023 まで 12 2024
